Efficacy and Safety of aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Treatment of hypertrophic cardiomyopathy (HCM) is generally focused on improving heart failure (HF) symptoms in patients with obstructive HCM (oHCM), with repurposed medicines, invasive septal reduction, and more recently targeted drug therapy with cardiac myosin inhibitors.1-4 However, among the one-third of patients with HCM who do not have left ventricular outflow tract (LVOT) obstruction, a substantial proportion develop symptoms that impact daily life and, in some cases, progress to end-stage HF requiring heart transplant.

Source: Journal of Cardiac Failure - March 14, 2024 Category: Cardiology Authors: Ahmad Masri, Mark V. Sherrid, Theodore P. Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M. Kramer, Roberto Barriales-Villa, Anjali T. Owens, Florian Rader, Sherif F. Nagueh, Iacopo Olivotto, Sara Saberi, Albree Tower-Rader, Timothy C. Wong, Ca Source Type: research